CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 2,515 enrolled
Drug / intervention
exenatide +1 moredrug
Likely dose
exenatide 5mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00635492
NCT00635492N/ACompleted
CompareCT.gov

CHOICE: CHanges to Treatment and Outcomes in Patients With Type 2 Diabetes Initiating InjeCtablE Therapy - A European Observational Study of Patients With Type 2 Diabetes Initiating Injectable Therapy to Determine Time to Treatment Change, Factors Associated With Treatment Changes and Outcomes Over 24 Months

AstraZeneca·observational·Posted Mar 13, 2008·Updated Apr 9, 2015

In Brief

An observational study evaluating exenatide and any human insulin or analog insulin(s) given in any regimen by subcutaneous injection for Type 2 Diabetes Mellitus. Completed, enrolled 2,515 participants across 96 sites in 5 countries.

Detailed Summary

Patients initiating injectable therapy for type 2 diabetes (insulin or exenatide) in usual clinical practice will be enrolled and followed up for two years in order to describe actual practice with regards to the time on initial treatment regime, whether treatment regimens are being modified, what treatment modifications are made, and clinical and patient-reported outcomes.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesDenmark, France, Germany, Greece, Sweden
CollaboratorsEli Lilly and Company

Timeline

N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 13, 2008
Enrollment StartJan 1, 2008
Primary CompletionDec 1, 2011
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 18.3 years ago

Interventions

exenatidedrug

subcutaneous injection, 5mcg or 10mcg, twice a day

any human insulin or analog insulin(s) given in any regimen by subcutaneous injectiondrug